AQST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aquestive Therapeutics Inc (AQST) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. The stock faces regulatory challenges, insider selling, and ongoing lawsuits, which introduce significant risks. While there is potential for future growth tied to Anaphylm's approval, the timeline for resubmission and approval stretches into late 2026, making it less suitable for an impatient investor.
The technical indicators suggest a bearish trend. The MACD is negative and expanding downward, RSI is neutral at 44.762, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 3.998, with resistance at 4.342. Overall, the technical setup does not indicate a strong buying opportunity.
Analysts maintain a Buy rating with price targets ranging from $6 to $9, indicating potential upside.
The FDA's Complete Response Letter (CRL) for Anaphylm does not highlight major concerns, and the company has a clear plan for resubmission by Q3
Revenue increased by 9.67% YoY in Q4 2025, showing some growth.
Insider selling has increased by 140.84% over the last month, signaling potential lack of confidence from company insiders.
Multiple class action lawsuits related to alleged securities fraud and regulatory issues are ongoing, which could impact investor sentiment.
Gross margin dropped by 10.90% YoY in Q4 2025, and the company remains unprofitable with a net income of -$31.86M.
In Q4 2025, revenue increased by 9.67% YoY to $13.015M, and net income improved by 86.81% YoY to -$31.86M. EPS also improved by 36.84% YoY to -0.26. However, gross margin declined to 55.16%, down 10.90% YoY, indicating cost pressures.
Analysts maintain a Buy rating but have lowered price targets due to the delay in Anaphylm's approval. Price targets range from $6 to $9, with the valuation heavily dependent on Anaphylm's future approval and commercialization.
